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Abstract 
Purpose: To delineate chronological changes of cortical hyperexcitability by long-term follow-up of 
the amplitudes of somatosensory evoked potentials (SEPs) in patients with Japanese 
Unverricht-Lundborg disease (ULD). 
Methods: SEPs to median nerve stimulation were repeatedly examined in 7 genetically diagnosed 
ULD patients with the mean interval of 11.9 years. The degree of temporal changes in the amplitude 
of 3 early cortical components, N20, P25 and N35, to the age was analyzed and compared with that 
of healthy subjects.  
Results: Their clinical course was almost stable during the follow-up period, namely cessation of 
generalised tonic-clonic seizures and little or no progression of myoclonus. SEP amplitudes of P25 
and N35 were enlarged in all patients and were gradually decreased with aging in ULD on average. 
The degree of temporal changes of P25 and N35 in ULD was similar or even lower than that of 
healthy subjects. 
Conclusions: Enlarged but relatively stable SEP amplitudes had a consistency with so-called 
self-limited clinical course in Japanese ULD. SEP amplitude could be one of the surrogate markers of 
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1. Introduction 
Unverricht-Lundborg disease (ULD) is one of progressive myoclonus epilepsies that is 
characterized by myoclonus, epileptic seizures and cerebellar ataxia, and nowadays is called 
progressive myoclonus epilepsy type 1 (EPM1)1). In ULD patients, the somatosensory evoked 
potentials (SEPs) usually show enhanced cortical components after N20 (i.e., giants SEPs) as a 
marker of cortical hyperexcitability to the external stimuli2),3). Although the term “progressive” was 
assigned, it was reported that the European ULD patients showed self-limited progression in the later 
life4). By investigating neurophysiological correlates of this clinical course, we just recently reported 2 
Japanese ULD patients who showed clinically no or little progressive course. Their bimodal 
waveforms of N35 in the previous SEPs became unimodal over the course of 16 years, and it 
suggests decreased cortico-cortical connectivity and/or cortical excitability5). We also reported the 
amplitudes of the early SEP components (N20, P25 and N35) were almost stable, although these 
components were already enlarged in the previous SEP. However, it is not certain whether waveform 
change of N35 is common or not because we studied only 2 patients. We could not evaluate the 
chronological changes in amplitudes of each cortical SEP component, either. Herewith we 
extensively evaluated 5 more genetically proven ULD patients. 
In this report, we further described the temporal changes in SEP amplitudes of a total of 7 
Japanese ULD patients to delineate the chronological changes of responsive, cortical 
hyperexcitability. Only abstract is available for this study6).  
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2. Patients and methods 
We recruited 7 Japanese patients with genetically diagnosed ULD (4 men and 3 women; 
mean age at the first SEP examination of 27.6 years, ranged from 17 to 42 years). During the 
follow-up period, we collected the changes in the frequency of generalised tonic clonic seizures 
(GTCSs), and the degree of myoclonus for each patient by using the simplified myoclonus rating 
scale as follows4), 0 = no myoclonus; 1 = minor myoclonus, no interference with daily living; 2 = mild 
myoclonus, interference with fine movements and/or speech, no interference with walking; 3 = 
moderate myoclonus, patient still able to walk without support; 4 = moderate to severe myoclonus, 
patient able to stand, unable to walk without support; 5 = severe myoclonus, patient 
wheelchair-bound or bedridden.  
The SEPs were not recorded with completely the same equipment and condition, since the 
patients belonged to several institutes and the repeated examination were done with the mean 
interval of 11.9 years (ranged from 4 to 16 years). Recording conditions were quite consistent at least 
within each patient. Furthermore, as compared with previous study5), the overall recording condition 
was essentially consistent except for stimulus frequency in several patients as follows. The median 
nerve was stimulated at the wrist at a fixed rate of 1.1-3.0 Hz (1.1 Hz in 3 patients and 2.0 Hz in 4 for 
the previous recording; 1.1 Hz in 5 and 3.0 in 2 for the present recording) and the stimulus intensity 
was adjusted to produce a clear twitch of the thenar muscle. Short latency SEPs were recorded from 
C3/C4 according to the International 10-20 System or CP3/CP4 by 10-10 System of the American 
6 
 
Kobayashi et al 7 
 
EEG Society. The electrode impedance was kept below 5kΩ. The ipsilateral earlobe to the stimulated 
hand (A1 or A2) or the linked earlobes (A1 + A2) were used as the reference. The bandpass filter 
was within the range of 0.5-3000 Hz. At least 200 responses were averaged.  
We adopted 3 components of N20, P25 and N35. Amplitudes of P25 and N35 were 
measured from the preceding opposite peak and those of N20 were measured from the baseline. An 
SEP was judged as “giant” when P25 was more than 6.3 µV or N35 was more than 9.8 µV7). We also 
compared the amplitudes of the 3 components of ULD patients in the previous and present states 
with those of healthy subjects (N=19; 11 men and 8 women; mean age at the SEP examination of 49 
years, ranged from 22 to 74 years) by Mann-Whitney U test. A tangential component of N30-P30 was 
not adopted in this study, since we could not detect the reliable N30-P30 from shortage of the 
number of the recorded electrodes. 
In order to evaluate the chronological changes in SEP amplitude in ULD, we compared the 
early cortical components of SEPs between previous and present states by Wilcoxon signed-rank 
test. In addition, we analyzed the relationship between the age at SEP recording and its amplitudes.  
Namely we calculated the averaged value of the ages and amplitudes of 7 patients both at previous 
and present SEP recording, and then extrapolated the chronological changes. Since SEP amplitude 
increased with aging even in healthy subjects8),9), we compared the gradient of ULD patients with 
those of 19 healthy subjects as reported previously9).  
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3. Results 
As for the clinical symptoms, all the patients showed a cessation of GTCSs and a stable or 
little worsened myoclonus. The medications at the previous and present SEP recording are shown in 
Table 1. During the follow-up period, the dosage of the medications did not show clear tendency. 
Namely, medication was increased in 4 patients (Patient 3, 4, 5, and 6) whereas it was decreased in 
3 patients (Patient 1, 2, and 7). The averaged simplified myoclonus rating scale of 7 patients 
indicated almost stable but moderately severe, 3.4 and 3.9 at the previous and present recording, 
respectively. 
In the previous recording, N20, P25 and N35 amplitudes (mean ± S.D.) in 7 ULD patients 
were 0.9 ± 0.9 µV, 10.5 ± 6.4 µV and 12.9 ± 7.0 µV, and those in the present evaluation were 2.3 ± 
1.6 µV, 9.9 ± 6.1 µV and 10.8 ± 4.0 µV, respectively (Table 2). Both in the previous and present 
recording, the amplitudes of N20 in ULD were lower than those of healthy subjects (p<0.05). On the 
other hand, the amplitudes of P25 and N35 in ULD were higher than those of healthy subjects and 
only N35 amplitudes reached statistical significance (p<0.05). All 7 patients fulfilled the criteria of the 
giant SEPs at least once during their clinical course.  
The amplitudes of P25 and N35 in some of the ULD patients tended to increase during the 
follow-up period, but no significant difference in amplitude was found between previous and present 
data by Wilcoxon signed-rank test. Whereas, only 1 patient (Patient 5) showed relatively drastic 
decrease in SEP amplitude for P25 and N35 (Fig. 1(b), (c)). In total, the gradients of temporal 
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changes of N20, P25 and N35 amplitudes for age in the 7 ULD patients were 0.119, -0.051, and 
-0.178, respectively. As compared with healthy subjects (N20: 0.048, P25: 0.139, N35: 0.089), that of 
P25 and N35, were even lower than those of healthy subjects (Fig. 1). Namely, enhanced amplitude 
of P25 and N35 reflects the responsive, cortical hyperexcitability across all the 7 patients, but the 
degree of its gradient in temporal change for aging is not increased at all. When 1 patient (Patient 5)  
was excluded because she showed dramatically decrease in amplitudes, the gradients of temporal 
changes of N20, P25 and N35 amplitudes for age in the 6 ULD patients were quite similar to those of 
aging in healthy subjects, i.e., 0.141, 0.156, and 0.073, respectively (not shown in the figure).  
The waveform change of N35 from bimodal to unimodal over the course was observed only 
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4. Discussion  
We demonstrated that SEP amplitudes were enlarged or giant in genetically diagnosed ULD 
patients throughout the follow-up period, that was quite consistent with previous reports. 
We also showed that once enlarged SEP amplitude of P25 and N35 gradually decreased on 
average with aging in ULD. Indeed, 5 patients for P25 and 4 patients for N35 demonstrated that 
enlarged SEP amplitude gradually increased with aging, but the degree of increment was quite 
comparable to that of aging in healthy subjects (Fig. 1). Namely, most likely we were able to 
demonstrate that responsive cortical hyperexcitability was not progressive for aging but relatively 
stable in the primary sensori-motor cortices in Japanese ULD. These electrophysiological findings in 
quite parallel with clinical course in our patients were quite consistent with self-limited clinical course 
as reported previously4). Therefore, SEP amplitude could be one of the surrogate markers of the 
degree of cortical excitability and at least a part of pathophysiology in ULD during the long-term 
follow-up period. However, It is unclear that self-limited progression was observed in all Japanese 
ULD patients, since one of the patients (Patient 5), who showed a little worsened myoclonus, showed 
relatively drastic decrease in SEP amplitude. It might be explained by the paradoxical association 
between giant SEP and the degree of myoclonus, which was clearly reported in patients with cortical 
myoclonus previously10). 
In addition, some ULD patients in other reports with genetically diagnosed show continuous 
progression in terms of clinical symptoms as well as electrophysiological results11). In our previous 
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report we mentioned the waveform change of N35 from bimodal to unimodal could reflect a lesser 
degree of cortico-cortical connectivity and/or decreased cortical hyperexcitability in ULD patients. 
The additionally recruited 5 patients did not show similar waveform change of N35 component, which 
suggests not only this waveform change but also chronological changes in SEP amplitudes 
contribute to self-limited progression. 
Further case accumulation showing variable clinical course is indispensable to further clarify 
the clinico-electorophysiological correlates and to solve these clinical questions in patients with ULD. 
The current long-term observation in this study started mostly after age 20 years in 6 out of 7 patients, 
but it was done until before 50 years in 6 out of 7 patients. Therefore, it may not be completely 
excluded that ULD patients in much older age more than 50 years are actually so stable. Thus, it is 
important to continue the evaluation of our patients to see if changes in SEP can manifest in older 
patients. 
There are several limitations in this study. Firstly, the change of SEP amplitude over a 
decade might be due to chronic exposure to antiepileptic or antimyoclonic drugs. In general, most 
antiepileptic drugs seem to decrease the SEP amplitude12). The dosages of these drugs were not 
completely the same during the follow-up period as well. Secondly, as mentioned in Methods, the 
recording conditions were not completely the same among studied patients and within each patient. 
However, except stimulus rate, we consider that the influence of the different recording conditions on 
the SEP amplitude was quite small. With regard to the stimulus rate, in the previous reports, the 
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amplitude of P25 decreased and N35 was not significantly altered once the stimulus rate gradually 
increased from 1.0 to 5.0 Hz13),14). In our study, the stimulus rate increased from 2.0 Hz to 3.0 Hz in 2 
patients (Patient 5 and 6), and that decreased from 2.0 Hz to 1.1 Hz in the other 2 patients (Patient 3 
and 4) between previous and present recordings. The change of amplitude, such as decreased 
amplitude of P25 only in Patient 5, might be partly influenced by the change of stimulus rate. Despite 
these limitations, our study has some value in evaluating long-term clinico-electorophysiological 
changes in Japanese ULD. 
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5. Conclusions  
 We demonstrated that SEP amplitudes were enlarged or giant in genetically diagnosed ULD 
patients throughout the follow-up period. We also showed that once enlarged SEP amplitude of P25 
and N35 gradually decreased with aging in ULD. Enlarged but relatively stable or gradually 
decreased SEP amplitudes had a consistency with so-called self-limited clinical course in ULD. SEP 
amplitude could be one of the surrogate markers of the degree of cortical hyperexcitability in ULD 




Kobayashi et al 14 
 
Acknowledgements 
 This work was partly supported by the Research Grant (22A-6) for Nervous and Mental 
Disorders from the Ministry of Health and Welfare, the Grants-in-Aid for Scientific Research 
(23591275) from the Japan Society for the Promotion of Science (JSPS), the Grants-in-Aid for 
Scientific Research (KAKENHI) (C) from the Ministry of Education, Culture, Sports, Science and 
Technology of Japan (25515001), and a Research Grant from The Japan Epilepsy Research 
Foundation. 
 
Disclosure of Conflicts of Interest 




Kobayashi et al 15 
 
References 
1) Kälviäinen, R., Khyuppenen, J., Koskenkorva, P., Eriksson, K., Vanninen, R., Marvaala, E., 2008. 
Clinical picture of EPM1 - Unverricht–Lundborg disease. Epilepsia. 49, 549-556. 
2) Shibasaki, H., Yamashita, Y., Neshige, R., Tobimatsu, S., Fukui, R., 1985. Pathogenesis of giant 
somatosensory evoked potentials in progressive myoclonic epilepsy. Brain. 108, 225-240. 
3) Canafoglia, L., Ciano, C., Panzica, F., Scaioli, V., Zucca, C., Agazzi, P., Visani, E., Avanzini, G., 
Franceschetti, S., 2004. Sensorimotor cortex excitability in Unverricht-Lundborg disease and Lafora 
body disease. Neurology. 63, 2309-2315. 
4) Magaudda, A., Ferlazzo, E., Nguyen, V.H., Genton, P., 2006. Unverricht-Lundborg disease, a 
condition with self-limited progression: long-term follow-up of 20 patients. Epilepsia. 47, 860-866. 
5) Kobayashi, K., Matsumoto, R., Kondo, T., Kawamata, J., Hitomi, T., Inouchi, M., Matsuhashi, M., 
Takahashi, R., Ikeda, A., 2011. Decreased cortical excitability in Unverricht-Lundborg disease in the 
long-term follow-up: A consecutive SEP study. Clin Neurophysiol. 122, 1617-1621. 
6) Kobayashi, K., Hitomi, T., Matsumoto, R., Kondo, T., Kawamata, J., Takahashi, R., Ikeda, A., 
Hashimoto, S., Ikeda, H., Koide, Y., Inoue, Y., 2010. Giant somatosensory evoked potentials in 
patients with Unverricht-Lundborg disease. Journal of the Japan Epilepsy Society. 28, 304 (abstract 
in Japanese). 
7) Ikeda, A., Shibasaki, H., Nagamine, T., Xu, X., Terada, K., Mima, T., Kaji, R., Kawai, I., Tatsuoka, Y., 
Kimura, J., 1995. Peri-rolandic and fronto-parietal components of scalp-recorded giant SEPs in 
15 
 
Kobayashi et al 16 
 
cortical myoclonus. Electroencephalogr Clin Neurophysiol. 96, 300-309. 
8) Lüders, H., 1970. The effects of aging on the wave form of the somatosensory cortical evoked 
potential. Electroencephalogr Clin Neurophysiol. 29, 450–460. 
9) Hitomi, T., Ikeda, A., Kondo, T., Imamura, H., Inouchi, M., Matsumoto, R., Terada, K., Kanda, M., 
Matsuhashi, M., Nagamine, T., Shibasaki, H., Takahashi, R., 2011. Increased cortical 
hyperexcitability and exaggerated myoclonus with aging in benign adult familial myoclonus epilepsy. 
Mov Disord. 26, 1509-1514.  
10) Rothwell, J.C., Obeso, J.A., Marsden, C.D., 1984. On the significance of giant somatosensory 
evoked potentials in cortical myoclonus. J Neurol Neurosurg Psychiatry. 47, 33-42. 
11) Chew, N.K., Mir, P., Edwards, M.J., Cordivari, C., Martino, D., Schneider, S.A., Kim, H.T., Quinn, 
N.P., Bhatia, K.P., 2008. The natural history of Unverricht-Lundborg disease: a report of eight 
genetically proven cases. Mov Disord. 23, 107-113. 
12) Erdem, H., Yigit, A., Culcuoglu, A., Mutluer, N., 2001. Effect of sodium valproate on 
somatosensory evoked potentials in juvenile myoclonic epilepsy. Ups J Med Sci. 106, 197-203. 
13) Huttunen, J., Homberg, V., 1991. Influence of stimulus repetition rate on cortical somatosensory 
potentials evoked by median nerve stimulation: implications for generation mechanisms. J Neurol Sci. 
105, 37-43. 
14) Garcia Larrea, L., Bastuji, H., Mauguiere, F., 1992. Unmasking of cortical SEP components by 
changes in stimulus rate: a topographic study. Electroencephalogr Clin Neurophysiol. 84, 71-83. 
16 
 





Kobayashi et al 18 
 
Figure Legends 
Figure 1. Correlation between the age at SEP recording and its amplitudes in 7 ULD patients. Values 
of N20 (A), P25 (B) and N35 (C) (different colored lines) and the gradients of their temporal changes 
drawn by calculating the averaged value of the ages and amplitudes between previous and present 
SEP recordings (black lines) in 7 patients are compared with linear regression curves of 19 healthy 
subjects (gray lines). 
N20 amplitudes were much smaller and P25 and N35 amplitudes larger in ULD patients. As for the 
components associated with giant SEP (i.e., P25 and N35), 7 ULD patients showed a tendency of 
slight decrease in amplitude during the follow-up period, and the degree of its tendency was even 








1) We followed SEP amplitudes in 7 Japanese Unverricht-Lundborg disease (ULD) patients. 
2) Clinical course of all patients was almost stable during the follow-up period. 
3) The SEP amplitudes were enlarged but relatively stable over 10 years. 
4) SEP amplitudes had a consistency with so-called self-limited clinical course in ULD. 





Medications at the previous and present SEP recording in 7 patients (mg/day).
Previous Present
Age at SEP Age at SEP
Patient 1 42 58
Patient 2 32 48
Patient 3 24 34
Patient 4 31 42
Patient 5 17 34
Patient 6 24 33
Patient 7 23 27
VPA: valproic acid, CZP: clonazepam, PB: phenobarbital, PHT: phenytoin, CBZ: carbamazepine, ZNS: zonisamide, DZP: diazepam, PRM: primidone, AZM: acetazolamide
   VPA 3,600, CZP 12, PHT 300, CBZ 400
   VPA 1,100, CZP 6, ZNS 200
   VPA 1,200, PB 90, ZNS 200
   VPA 1,400, PB 50, ZNS 200
   VPA 600, CZP 2, Piracetam 12,000
   VPA 1,200, CZP 1.3, PB 40, PRM 400
   VPA 800, CBZ 200
   VPA 800, CZP 2, Piracetam 12,000
   VPA 700, CZP 6, PB 60, Piracetam 6,000
   VPA 2,000, CZP 8, ZNS 300, DZP 5
   VPA 1,800, CZP 6, ZNS 200, Piracetam 33,000
   VPA 1,200, CZP 6, PB 60, ZNS 200, Piracetam 27,000
   VPA 1,800, CZP 4, ZNS 600, PRM 300, AZM 250
   VPA 1,400, CZP 4.5, PB 120, Piracetam 15,000
Table 2
Latency and amplitude of cortical components of SEPs in 7 patients, latency (ms) / amplitude (µV).
Previous Present
Age at SEP N20 P25 N35 Age at SEP N20 P25 N35
Patient 1 42 20.6 / 1.3 26.6 / 6.6* 30.9 / 10.3* 58 20.1 / 2.5 25.4 / 9.5* 30.8 / 10.9*
Patient 2 32 19.2 / 0.2 24.8 / 5.5 31.5 / 11.8* 48 20.7 / 0.8 24.9 / 4.7 32.3 / 13.0*
Patient 3 24 23.7 / 0.0 29.1 / 5.2 37.9 / 8.3 34 20.6 / 2.0 25.3 / 6.0 31.4 / 10.0*
Patient 4 31 23.8 / 0.4 32.0 / 17.4* 38.7 / 19.7* 42 20.9 / 5.1 26.6 / 22.4* 33.1 / 18.2*
Patient 5 17 20.0 / 0.2 26.0 / 21.0* 32.6 / 24.8* 34 20.3 / 1.1 25.8 / 6.6* 31.0 / 5.6 
Patient 6 24 20.4 / 2.3 26.6 / 5.8 34.9 / 4.7 33 20.5 / 1.3 27.4 / 7.8* 35.3 / 7.6 
Patient 7 23 14.2 / 1.8 20.2 / 11.9* 31.8 / 10.4* 27 18.5 / 3.6 24.0 / 12.3* 32.7 / 10.3*
Average ± S.D. 27.6 20.3 ± 3.2 / 0.9 ± 0.9 26.5 ± 3.6 / 10.5 ± 6.4 34.0 ± 3.2 / 12.9 ± 7.0 39.4 20.2 ± 0.8 / 2.3 ± 1.6 25.6 ± 1.1 / 9.9 ± 6.1 32.4 ± 1.5 / 10.8 ± 4.0 
* Giant SEP: P25 > 6.3 or N35 > 9.8 µV (Ikeda et al., 1995)
